Helex Septal Occluder for Closure of Atrial Septal Defects
- PMID: 11096676
Helex Septal Occluder for Closure of Atrial Septal Defects
Abstract
The HELEX Septal Occluder (W.L. Gore and Associates, Flagstaff, AZ) is a new device with many desirable characteristics. These include direct placement of the delivery catheter across the septal defect without the need for a long sheath; rounded, flexible and atraumatic shape; easy deployment while maintaining the ability to withdraw the device back into the delivery system at any time prior to release; safety cord to allow for removal of the device even after release from the formed elements of the delivery system; and highly biocompatible expanded polytetrafluoroethylene (ePTFE) covering. The design of the device has been thoroughly tested by computer modeling, in vitro testing, and in vivo evaluations in an animal model of atrial septal defect (ASD). Early human experience in Europe for ASD and patent foramen ovale (PFO) indications has been encouraging. Food and Drug Administration (FDA) trials in the United States are anticipated this year.
Similar articles
-
Results of the U.S. Food and Drug Administration continued access clinical trial of the GORE HELEX septal occluder for secundum atrial septal defect.JACC Cardiovasc Interv. 2014 Aug;7(8):905-12. doi: 10.1016/j.jcin.2014.01.169. JACC Cardiovasc Interv. 2014. PMID: 25147036 Clinical Trial.
-
The design and deployment of the HELEX septal occluder.Congenit Heart Dis. 2006 Sep;1(5):202-9. doi: 10.1111/j.1747-0803.2006.00036.x. Congenit Heart Dis. 2006. PMID: 18377527
-
Single centre experience with GORE-HELEX septal occluder for closure of PFO.Heart Lung Circ. 2009 Apr;18(2):140-2. doi: 10.1016/j.hlc.2007.11.141. Epub 2008 Feb 21. Heart Lung Circ. 2009. PMID: 18294910
-
Combined prospective United States clinical study data for the GORE(®) HELEX(®) septal occluder device.Catheter Cardiovasc Interv. 2014 May 1;83(6):944-52. doi: 10.1002/ccd.24987. Epub 2014 Jan 31. Catheter Cardiovasc Interv. 2014. PMID: 23674380 Review.
-
The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.Circ Cardiovasc Interv. 2018 Mar;11(3):e004152. doi: 10.1161/CIRCINTERVENTIONS.117.004152. Circ Cardiovasc Interv. 2018. PMID: 29870380 Review.
Cited by
-
Outcomes of Device Closure of Atrial Septal Defects.Children (Basel). 2020 Aug 25;7(9):111. doi: 10.3390/children7090111. Children (Basel). 2020. PMID: 32854325 Free PMC article. Review.
-
Experience with transcatheter closure of secundum atrial septal defects using the Amplatzer septal occluder: a single centre study in 236 consecutive patients.Heart. 2003 Feb;89(2):199-204. doi: 10.1136/heart.89.2.199. Heart. 2003. PMID: 12527678 Free PMC article.
-
First experience with the 2005 modified Gore Helex ASD occluder system.Clin Res Cardiol. 2006 Sep;95(9):468-73. doi: 10.1007/s00392-006-0413-8. Epub 2006 Jul 20. Clin Res Cardiol. 2006. PMID: 16845573
-
Use of the transseptal puncture in transcatheter closure of long tunnel-type patent foramen ovale.Heart. 2002 Aug;88(2):E3. doi: 10.1136/heart.88.2.e3. Heart. 2002. PMID: 12117864 Free PMC article.
-
[Interventional closure of atrial septal defects, patent oval foramen and ventricular septal defects].Herz. 2015 Aug;40(5):765-70. doi: 10.1007/s00059-015-4331-2. Herz. 2015. PMID: 26135465 Review. German.